Becton Dickinson Posts 7 Percent Q2 Growth | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues grew 7 percent, led by its BD Medical segment

The Franklin Lakes, NJ-based firm reported total revenues of $1.84 billion for the three-month period ended March 31, compared to $1.72 billion for Q1 2009. The firm fell just short of analysts' consensus expectations for revenues of $1.85 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.